SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
analysts and calls -- B of A
An SI Board Since September 2002
Posts SubjectMarks Bans
33 11 0
Emcee:  scaram(o)uche Type:  Moderated
Introduction Compact
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
8Neurocrine Biosciences downgraded by Banc of America Sec - Briefing.com. From StIcebrg-11/15/2002
7He also started ITMN with strong buy and REGN with buy.Miljenko Zuanic-10/15/2002
6RESEARCH ALERT-Banc of America starts biopharmaceuticals Tuesday October 15, 11:Icebrg-10/15/2002
5RESEARCH ALERT-Banc of America starts biopharmaceuticals Tuesday October 15, 11scaram(o)uche-10/15/2002
4At one time, their name was Oncogene Sciences. They changed their name, to OSI,scaram(o)uche-9/25/2002
3Banc of America Securities analyst <b>Mike King upgraded OSI to buy from mIcebrg-9/25/2002
2>> Hope this was what you were looking for. << Yes! And I agree wiscaram(o)uche-9/20/2002
1James Reddoch and Mike King King covers mostly product companies and top tier JFitnich-9/20/2002
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News